Nobuo Nagai Selected Research

Infarction (Infarctions)

3/2008	Protective role of reactive astrocytes in brain ischemia.
8/2007	Microplasmin and tissue plasminogen activator: comparison of therapeutic effects in rat stroke model at multiparametric MR imaging.
9/2003	Survivin-dependent angiogenesis in ischemic brain: molecular mechanisms of hypoxia-induced up-regulation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nobuo Nagai Research Topics

Disease

9	Stroke (Strokes) 12/2015 - 09/2003
5	Ischemic Stroke 01/2016 - 02/2008
4	Brain Ischemia (Cerebral Ischemia) 01/2016 - 04/2004
4	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 12/2015 - 06/2002
4	Ischemia 01/2011 - 09/2003
4	Thrombosis (Thrombus) 01/2008 - 12/2004
3	Infarction (Infarctions) 03/2008 - 09/2003
3	Obesity 01/2008 - 10/2007
2	Hemorrhage 01/2011 - 10/2009
2	Neurodegenerative Diseases (Neurodegenerative Disease) 04/2010 - 03/2008
2	Retinal Neovascularization 04/2009 - 03/2008
1	Reperfusion Injury 01/2016
1	Brain Injuries (Brain Injury) 12/2015
1	Neoplasms (Cancer) 01/2015
1	Cerebral Infarction 01/2012
1	Animal Disease Models 01/2012
1	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2011
1	Pathologic Neovascularization 04/2009
1	Venous Thrombosis (Deep-Vein Thrombosis) 01/2008
1	Body Weight (Weight, Body) 01/2008
1	Thrombotic Stroke 10/2004
1	Cerebral Hemorrhage 04/2004
1	Hypoxia (Hypoxemia) 09/2003

Drug/Important Bio-Agent (IBA)

8	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2016 - 06/2002
4	Matrix Metalloproteinases (MMPs)IBA 01/2016 - 04/2004
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2015 - 09/2003
2	Proteins (Proteins, Gene)FDA Link 01/2015 - 04/2010
2	Pharmaceutical PreparationsIBA 01/2012 - 01/2011
2	Vascular Endothelial Growth Factor BIBA 04/2009 - 03/2008
2	Plasminogen Activator Inhibitor 1IBA 03/2008 - 01/2008
2	microplasminIBA 08/2007 - 10/2004
2	Fibrinolysin FDA Link 06/2005 - 10/2004
1	LDL Receptors (LDL Receptor)IBA 12/2015
1	Dynactin ComplexIBA 01/2015
1	Messenger RNA (mRNA)IBA 01/2015
1	Cadherins (E-Cadherin)IBA 01/2015
1	Oncogene Proteins (Oncogene Protein)IBA 01/2015
1	Coloring Agents (Dyes)IBA 01/2012
1	Evans Blue (Blue, Evans)FDA Link 01/2012
1	Fibrinolytic Agents (Antithrombotic Agents)IBA 01/2011
1	NeurotoxinsIBA 04/2010
1	platelet-derived growth factor C (PDGF-C)IBA 04/2010
1	Matrix Metalloproteinase 3 (Stromelysin 1)IBA 10/2009
1	Endothelin B ReceptorIBA 03/2008
1	Glutamic Acid (Glutamate)FDA Link 03/2008
1	Urokinase Plasminogen Activator ReceptorsIBA 02/2008
1	rofecoxib (Vioxx)FDA Link 01/2008
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2008
1	ferric chlorideIBA 01/2008
1	Factor V (Coagulation Factor V)IBA 01/2008
1	factor V LeidenIBA 10/2007
1	Therapeutic UsesIBA 08/2007
1	Gadolinium DTPA (Magnevist)FDA Link 12/2004
1	Heparin (Liquaemin)FDA LinkGeneric 04/2004
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 04/2004
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 09/2003
1	SurvivinIBA 09/2003

Therapy/Procedure

3	Therapeutics 01/2015 - 04/2004
2	Thrombolytic Therapy 12/2015 - 04/2004
1	Treatment Delay 01/2011
1	Axotomy 04/2010